share_log

CompuMed Integrates the Techcyte Digital Pathology Reviewing Platform to Help Increase Transplanted Organs

CompuMed Integrates the Techcyte Digital Pathology Reviewing Platform to Help Increase Transplanted Organs

CompuMed 集成了 Techcyte 數字病理學審查平台以幫助增加移植器官
Accesswire ·  2023/10/24 09:00

LOS ANGELES, CA / ACCESSWIRE / October 23, 2023 / Techcyte, the world leader in AI-based cellular digital diagnostics, is pleased to announce a collaboration with CompuMed to enhance the digital manual review of available livers and kidneys for organ transplantation. As a leader in diagnostic telemedicine, CompuMed prides itself on providing remote pathology reads anywhere, at any time. To further its mission and better serve its partners in the donation and transplantation community, CompuMed has adopted the Techcyte digital reviewing platform, a feature of Techcyte's clinical pathology AI platform.

加利福尼亞州洛杉磯/ACCESSWIRE/2023年10月23日/基於人工智慧的細胞數位診斷領域的世界領先者Techcell很高興地宣佈與CompuMed合作,加強對可用於器官移植的肝臟和腎臟的數位手動審查。作為診斷遠端醫療領域的領導者,CompuMed以隨時隨地提供遠端病理閱讀而自豪。為了進一步履行其使命,並更好地為捐贈和移植社區的合作夥伴提供服務,CompuMed採用了Techcell數位審查平臺,這是Techcell臨床病理AI平臺的一個功能。

Organ transplantation remains the gold standard for managing end-stage organ failure, but the demand for transplantable organs significantly outweighs the supply. According to OPTN/SRTR data, in 2021 nearly 25% of recovered organs are not utilized for transplantation, with this issue worsening over time.

器官移植仍然是治療終末期器官衰竭的黃金標準,但對可****的需求遠遠超過了供應。根據OPTN/SRTR的數據,2021年,近25%的回收器官未用於移植,隨著時間的推移,這一問題日益惡化。

A leading cause of the nonuse of viable organs is inconsistent biopsy reports. Reading biopsies from deceased donors is complex, and many hospitals lack the staffing and donor volumes to provide consistent and accurate data for surgeons and transplant teams to make informed decisions. CompuMed board-certified liver and kidney pathologists will use the Techcyte digital reviewing platform to conduct improved specialized digital reviews of frozen biopsies remotely to provide more standardized information so that more organs are made available for transplant.

活體器官未被使用的一個主要原因是活檢報告不一致。讀取已故捐贈者的活組織檢查很複雜,許多醫院缺乏人員配備和捐贈者數量,無法為外科醫生和移植團隊提供一致和準確的數據,以便做出明智的決定。CompuMed董事會認證的肝腎病理學家將使用Techcell數位審查平臺,遠端對冷凍活檢進行改進的專門數位審查,以提供更標準化的資訊,從而使更多的器官可用於移植。

In crucial time-sensitive settings like operating rooms where every second counts, organ procurement teams will digitize and upload organ tissue slides onto CompuMed's secure cloud network. Available round-the-clock, CompuMed's sub-specialist pathologists will review these slides on Techcyte's platform, tagging key biopsy parameters, directly linking them to digital images, and sharing the documented images in their reports. This streamlined process will allow transplant surgeons to swiftly validate biopsy findings, bolstering their decision-making confidence and thereby enhancing the prospects of saving the life of waiting patients.

在關鍵的時間敏感環境中,比如分秒必爭的手術室,器官採購團隊將把器官組織幻燈片數位化並上傳到CompuMed的安全雲網絡上。CompuMed的專科病理學家將在Techcell的平臺上審查這些幻燈片,標記關鍵的活檢參數,將它們直接鏈接到數位圖像,並在他們的報告****享記錄的圖像。這一簡化的流程將使移植外科醫生能夠迅速驗證活檢結果,增強他們的決策信心,從而增加挽救等待治療的患者生命的前景。

Ben Cahoon, CEO of Techcyte, remarks, "Our partnership with CompuMed showcases Techcyte's commitment to leveraging technology to advance digital diagnostics, thereby contributing positively to the transplantation community's lifesaving endeavors."

Techcell的首席執行官Ben Cahoon說:“我們與CompuMed的夥伴關係展示了Techcell致力於利用技術推進數位診斷,從而為移植社區的救生努力做出積極貢獻。”

"CompuMed's collaboration with Techcyte signifies a pivotal moment in the field of transplantation, offering the promise of better organ graft evaluation and higher success rates," says Lee Keddie, CEO of CompuMed. "By leveraging technology to enhance the assessment of transplant organs, this collaboration aims to reshape the landscape of organ transplantation, allowing quicker, more accurate decisions, increasing the organs transplanted, and ultimately, saving more lives."

CompuMed的首席執行官Lee Keddie說:“CompuMed與Techcell的合作標誌著移植領域的一個關鍵時刻,提供了更好的器官移植評估和更高的成功率的前景。通過利用技術來加強對****的評估,這一合作旨在重塑器官移植的格局,使之能夠更快、更準確地做出決定,增加移植的器官,並最終挽救更多的生命。

###

###

About Techcyte

關於Techcell

Techcyte, Inc. was founded in 2013 in Orem, Utah, and is the world leader in AI-based cellular digital diagnostics. Techcyte's Clinical Pathology AI Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal, and environmental clinics and labs.

Techcell,Inc.於2013年在猶他州奧雷姆成立,是基於人工智慧的蜂窩數位診斷領域的世界領先者。Techcell的臨床病理AI平臺使用深度機器學習來執行整個載玻片顯微鏡圖像的自動分析,為人類、動物和環境診所和實驗室帶來了數位診斷的革命性變化。

Techcyte's clinical pathology platform is for Research Use Only in the United States.

Techcell的臨床病理平臺僅在美國用於研究。

About CompuMed

關於CompuMed

CompuMed is the go-to provider of clinical organ analysis, offering rapid diagnostic reads by industry-best expert physicians through a seamless platform and process. With a commitment to service, innovation, and excellence, CompuMed is dedicated to helping save more lives. CompuMed, Inc. (OTCPink: CMPD) Diagnostic Telemedicine services provide our customers with the highest level of clinical care. Its telecardiology, telepathology, teleradiology and telepulmonology offerings provide real-time access to U.S. board-certified specialists through cloud-based technology 24/7/365.

CompuMed是臨床器官分析的首選提供商,通過無縫平臺和流程為行業最佳的專家醫生提供快速診斷讀取。CompuMed致力於服務、創新和卓越,致力於幫助拯救更多的生命。CompuMed,Inc.(OTCPINK:CMPD)診斷遠端醫療服務為我們的客戶提供最高水準的臨床護理。其遠端心血管學、遠端病理學、遠端放射學和心電圖像學產品通過基於雲的技術全天候提供對美國董事會認證專家的實時訪問。

For more information about how CompuMed's services and technologies helps OPO's contact:

有關CompuMed的服務和技術如何幫助OPO聯繫的更多資訊:

sales@compumedinc.com
310-258-5000

郵箱:Sales@Compumedinc.com
310-258-5000

SOURCE: CompuMed, Inc.

資料來源:CompuMed公司


View source version on accesswire.com:
在Accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論